助手标题
全文文献 工具书 数字 学术定义 翻译助手 学术趋势 更多
查询帮助
意见反馈
共[19]条 当前为第1条到19条
 

相关语句
chronic hepatitis gravis
    Study on Hemodynamic Changes of Portal Vein System in Chronic Hepatitis Gravis
    慢性重型肝炎门静脉系统血流动力学变化的研究
    Clinical study on phentolamine-mesilate combined diammonium-glycyrrhizinate in the treatment of chronic hepatitis gravis.
    酚妥拉明联合甘利欣治疗慢性重型肝炎的临床研究
    Analysis on serum cholinesterase in 132 patients with chronic hepatitis gravis
    132例慢性重型肝炎患者血清胆碱酯酶分析
    Study on the prevention and treatment of the abnormal phenomena during plasma exchange therapy on chronic hepatitis gravis
    血浆置换治疗慢性重型肝炎中防治异常现象的探讨
    Materials and Methods: The hemodynamics of portal vein system was assessed by Doppler ultrasound in 30 cases of chronic hepatitis gravis,51 normal, 61 chronic hepatitis, 46 compensated, and 36 decompensated cirrhosis.
    材料和方法 :应用多普勒超声检测 3 0例慢性重型肝炎患者门静脉系统血流动力学变化 ,并与正常组 ( 5 1例 )、慢性肝炎组 ( 61例 )、代偿期肝硬化组 ( 4 6例 )、失代偿期肝硬化组 ( 3 6例 )进行对照研究。
    The response rates of acute and chronic hepatitis gravis were 61.5% and 25.6% respectively,and the response rates of chronic hepatitis gravis in early stage,middle stage and late stage were 72%、42%、0% respectively. Conclusions The ALSS is effective in treating hepatitis gravis.
    急性、慢性重型肝炎应用ALSS治疗治愈好转率分别为 6 1.5 %、2 5 .6 % ,慢性重型肝炎早、中、晚期治疗治愈好转率分别为 72 %、4 2 %、0 %。
    30 patients with chronic hepatitis gravis were randomly divided into treated group and control group.
    30例慢性重型肝炎患者 ,随机分为治疗组和对照组。
    Objective To evaluate the clinical value of serum cholinesterase(CHE) activity for the estimation of curative effect and prognosis of chronic hepatitis gravis.
    目的探讨血清胆碱酯酶(CHE)活性对慢性重型肝炎患者的疗效估计及预后判断的临床价值。
    Methods One hundred and thirty-two patients with chronic hepatitis gravis were divided into good and bad prognosis groups,the change of serum CHE before and after treatment was compared.
    方法将132例慢性重型肝炎患者,根据预后及转归情况分为预后好及预后差2组,统计两组治疗前后血清CHE活性的变化。
    They were found in serum with only TTV DNA positive or with positive for multiple markers of TTV and hepatitis A virus(HAV) or hepatitis B virus(HBV) or hepatitis C virus(HCV) or hepatitis E virus(HEV) or hepatitis G virus(HGV). The clinical types of viral hepatitis with both TTV and HBV markers positive included the cases of chronic hepatitis gravis or cirrhosis.
    可呈TTV +HAV、TTV +HBV、TTV +HEV、TTV +HAV +HBV、TTV +HBV +HCV、TTV +HBV +HEV、TTV +HBV +HGV重叠感染 ,与HBV重叠感染可有慢性重型肝炎、肝硬化之临床类型 ;
    Conclusion TTV may play some role in chronic hepatic injury,contributing to the development of chronic hepatitis and having certain relationship with the formation of cirrhosis or chronic hepatitis gravis.
    结论 TTV在肝脏慢性损伤中可能起一定作用 ,可引起慢性肝炎并与肝硬化和慢性重型肝炎的发生相关联。
    Methods: Serum IL 6 level、procollagenⅢ(PCⅢ) and collagenⅣ(ⅣC) of 76 patients suffering chronic hepatitis B(CHB) or cirrhosis of the lives (LC) or chronic hepatitis gravis (CSH) were assayed by ELISA and RIA.
    方法 :采用 EL ISA法和放免法对 76例慢性乙型肝炎 (CHB)、肝炎肝硬化 (L C)、慢性重型肝炎 (CSH)患者血清 IL- 6和 型前胶原蛋白 (PC )及 型胶原蛋白 ( C)测定 ,肝活检 42例进行肝组织病理学分析。
    Conclusion: Chronic hepatitis gravis is apt to form acute portal hypertension with decreased perfusion of portal vein system thus causing liver in a state of lacking of blood and oxygen.
    结论 :慢性重型肝炎容易形成门静脉高压 ,门静脉血流灌注量明显减少 ,造成肝脏微循环障碍。
    Conclusion: Plasma exchange is high risk factor for SENV infection SENV is not a causative agent of chronic hepatitis gravis.
    结论:SENV可通过血浆置换方式传播,但混合SENV感染不影响慢性重型肝炎患者肝脏病变。
    Methods 42 patients suffering from chronic hepatitis gravis received a combined hepatotheragy with plasma exchange.
    方法对42例慢性重型肝炎患者在综合保肝治疗基础上给予血浆置换治疗。
    Objective To observe the efficacy as well as the mechanism of artificial liver-plasmapheresis in the treatment of chronic hepatitis gravis.
    目的 :观察人工肝血浆置换疗法对慢性重型肝炎的疗效。
    It is more suitable to use ALSS in early and middle stage of chronic hepatitis gravis. And ALSS may significantly decrease the levels of pathologic components such as TNF-α、endotoxin and nitrogen monoxide. As a result,ALSS can also alleviate the injury from immunoreaction and increase the survival rate.
    结论 ALSS治疗重型肝炎疗效可靠 ,急性重型肝炎的治疗效果较好 ,慢性重型肝炎在早、中期治疗最为适宜 ,并能降低TNF -α、内毒素及NO等病理成分 ,从而减轻重型肝炎时免疫反应对肝细胞的损伤 ,能明显提高其生存率。
    To observe the clinical efficacy of Phentolamine-Mesilate combined Diammonium-Glycyrrhizinate in the treatment of chronic hepatitis gravis.
    观察酚妥拉明联合甘利欣治疗慢性重型肝炎的疗效。
    Phentolamine-Mesilate combined Diammonium-Glycyrrhizinate has good clinical efficacy in the treatment of chronic hepatitis gravis.
    酚妥拉明联合甘利欣治疗慢性重型肝炎降低胆红素、提高凝血酶原活动度有较好的疗效
 

首页上一页1下一页尾页 

 
CNKI主页设CNKI翻译助手为主页 | 收藏CNKI翻译助手 | 广告服务 | 英文学术搜索
版权图标  2008 CNKI-中国知网
京ICP证040431号 互联网出版许可证 新出网证(京)字008号
北京市公安局海淀分局 备案号:110 1081725
版权图标 2008中国知网(cnki) 中国学术期刊(光盘版)电子杂志社